Diagnosis and treatment of chronic cerebral ischemia (clinical discussion)
https://doi.org/10.21518/2079-701X-2018-18-44-49
Abstract
The article presents a clinical case of diagnosis and treatment of the initial presentations of chronic cerebral ischemia (CCI) in the form of cognitive impairments in a middle-aged patient. The authors describe such features of cognitive impairments (CI) as the predominance of «subcortical» symptoms (bradyfrenia, fluctuation), which is typical for CCI. The article presents modern approaches to the diagnosis of CCI, according to which it is necessary to focus on the assessment of higher brain functions, while the significance of «focal microsymptoms» is not large. The article discusses the treatment issues of CCI, which should first include the achievement of the maximum possible control over the underlying vascular disease. It also provides the results of recent studies of the effectiveness of pathogenetic neurometabolic therapy for vascular CIs.
About the Authors
V. V. Zakharov
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
N. V. Vakhnina
Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Vascular diseases of the nervous system. Under the editorship of Schmidt EV. M.: Medicine, 1975.
2. Vereshchagin NV, Morgunov VA, Gulevskaya TS. Cerebrovascular pathology in atherosclerosis and arterial hypertension. M.: Medicine, 1997.
3. Pantoni L, Garsia J. Pathogenesis of leukoaraiosis. Stroke, 1997, 28: 652-659.
4. Martynov AI, Shmyrev VI, Ostroumova OD, et al. Features of cerebral white matter lesions in elderly patients with arterial hypertension. Klinicheskaya Meditsina, 2000, 6: 11-15.
5. Damulin IV, Parfenov VA, Skoromets AA, Yakhno NN. Circulatory disorders in the brain and spinal cord. In the book: Nervous system diseases. A guide for practitioners. Yahno NN, Shtulman DR. (ed.). M., 2003: 231-302.
6. Levin OS. Dyscirculatory encephalopathy: an anachronism or clinical reality? Sovremennaya Terapiya v Psikhiatrii i Nevrologii, 2012, 3: 40-46.
7. Levin OS. Dyscirculatory encephalopathy: current understanding of the mechanisms of development and treatment. Consilium Medicum, 2007, 8: 72-79.
8. Yakhno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data with dyscirculatory encephalopathy. Message 2: Cognitive impairment. Nevrol. Zhurn. 2001.6 (3): 10-19.
9. Rockwood K, Wentzel C, Hachinscki V et al. Prevalence and outcomes of vascular cognitive impairment. Neurology, 2000, 54: 447-451.
10. Bowler JV, Hachinski V. The concept of vascular cognitive impairment. In T.Erkinjuntti, S.Gauthier (eds).Vascular cognitive impairment. Martin Dunitz, 2002: 9-26.
11. Yakhno NN, Zakharov VV, Lokshina AB. Moderate cognitive impairment syndrome in dyscirculatory encephalopathy. Zhurnal Nevrol. i Psikhiatr. im. S.S. Korsakova 2005, 105 (2): 13-17.
12. Preobrazhenskaya IS, Yakhno NN. Vascular cognitive impairment: clinical manifestations, diagnosis, treatment. Nevrologichesky Zhurnal, 2007, 12 (5): 45-50.
13. O’Brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurology, 2003; 2: 89-98.
14. Yakhno NN, Lokshina AB, Zakharov VV. Mild and moderate cognitive impairment in dyscirculatory encephalopathy. Nevrologichesky Zhurnal, 2004, 2: 30-35.
15. Van der Flier WM, van Straaten ECW, Barkhof F et al. (LADIS Study Group). Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. The LADIS Study. Stroke, 2005, 36: 2116-2120.
16. Roman GC, Erkinjuntti T, Wallin A et al. Subcortical ischemic vascular dementia. Lancet Neurology, 2002; 1: 426-36.
17. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Cognitive disorders. M: Remedium Group, 2014: 192.
18. Yakhno NN, Zakharov VV, Lokshina AB, Koberskaya NN, Mkhitaryan EA. Dementia: a guide for practitioners. M.: Medpress-inform, 2011: 264.
19. Shvareva IS, Alekseev VV, Yakhno NN. Headaches attributed to hypertension. Biomedicinskie Tekhnologii i Radioelektronika, 2002, 8: 4-10.
20. Alekseev VV, Shvareva IS, Parfenov VA, Ryzhak AA. Headache in patients with arterial hypertension. Klinicheskaya Gerontologiya, 2001, 5: 3-9.
21. Vakhnina NV, Milovanova OV. Neurological disorders in patients with hypertension and their correction. Nevrologiya, Neyropsikhiatriya, Psikhosomatika, - 2106, 8 (4): 32-37.
22. Яхно Н.Н., Левин О.С., Дамулин И.В. Сопоставление клинических и МРТ-данных при дисциркуляторной энцефалопатии. Сообщение 1: двигательные нарушения. Неврол. журн., 2001, 6(2): 10-16. /Yakhno NN, Levin OS, Damulin IV. Comparison of clinical and MRI data in dyscirculatory encephalopathy. Message 1: motor impairment. Nevrol. Zhurn. 2001, 6 (2): 10-16.
23. Damulin IV, Bryzzhakhina VG, Yakhno NN. Gait and balance disorders in dyscirculatory encephalopathy. Clinical neuropsychological and MRI comparison. Nevrol. Zhurn, 2004, 4: 13-18.
24. Sudo FK, Amado P, Alves GS et al. A continuum of executive function deficits in early subcortical vascular cognitive impairment: A systematic review and meta-analysis. Dement Neuropsychol, 2017 December; 11(4): 371-380.
25. Foster V, Oakley AE, Slade JY et al. Pyramidal neurons in the prefrontal cortex in post-stroke, vascular and other age-related dementias. Brain, 2014, 137: 2509-2521.
26. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanism linking vascular disease and depression. Mol Psychiatry,2013, 18(9):– 963-974.
27. Elminger MW, Kriebel M, Zigler D. Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro. Neuromolecular Med., 2011, 13: 266-274.
28. Fedorovich AA. Non-invasive evaluation of microvascular endothelium in human skin. Microvascular research, 2012, 84: 86-92.
29. Guekht AB, Skoog I, Edmundson S et al. ARTEMIDA trial (a randomized trial of efficacy 12 months international double blind actovegin). A randomized controlled trial to assess the efficacy of actovegin in post-stroke cognitive impairment. Stroke, 2017, 48(5): 1262-1270.
30. Ostroumova OD. Use of Actovegin for the correction of cognitive impairment in hypertensive patients. Med. Alfavit, 2012, 4: 4-8.
31. Gavrilova SI, Selezneva ND, Roshchina IF, Kalyn YB, Mikhailova NM. Study of the efficacy and safety of Aktovegin in elderly patients with a mild cognitive impairment syndrome of cerebrovascular origin. Psykhiatria, 2009, 1: 37-50.
32. Oswald WD, Steyer W, Oswald B, Kuntz G. Die verbesserung fluider kognitiver leistungen als imdikator fur die klinishe wirksamkeit einer nootropen substanz. Eine placebokontrollierte doppelblind studie mit Actovegin. Z. Gerontopsychol Psychiatric, 1991, 4: 209-220.
33. Jansen V., Bruckner GV. Treatment of chronic cerebrovascular insufficiency using Actovegin Forte pills (double-blind, placebocontrolled study). RMJ, 2002, 10 (12-13): 543-546.
34. Saletu B, Grunberger J, Linzmayer L et al. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2 weeks infusions with the hemoderivative Actovegin: double blind placebo controlled trials. Neuropsychobiol., 1990-1991, 24: 135-145.
35. Herman VM, Bon-Schelchevsky VJ, Kuntu G. Actovegin infusion therapy in patients with primary degenerative dementia of the Alzheimer type and multi-infarct dementia (Results of prospective placebocontrolled double-blind study in hospitalized patients). RMJ, 2002, 10 (15): 658-663.
36. Kanowski S, Kinzler E, Lehman E et al. Confirmed clinical efficacy of actovegin in elderly patients with organic brain syndrome. Pharmocopsychiat. 1995, 28: 125-133.
Review
For citations:
Zakharov VV, Vakhnina NV. Diagnosis and treatment of chronic cerebral ischemia (clinical discussion). Meditsinskiy sovet = Medical Council. 2018;(18):44-49. (In Russ.) https://doi.org/10.21518/2079-701X-2018-18-44-49
Views:
1015
Email this article 